Used as a targeted anticancer agent, particularly in the treatment of chronic myeloid leukemia (CML). It functions by inhibiting the BCR-ABL tyrosine kinase, the abnormal protein responsible for the uncontrolled growth of leukemic cells. Due to its high selectivity and potency, it is considered effective in patients who are resistant or intolerant to other tyrosine kinase inhibitors like imatinib. It has shown promising results in clinical trials, improving hematologic and cytogenetic responses. Its oral bioavailability allows for convenient outpatient treatment, contributing to its use in long-term management of CML.